Abstract This study underlines the importance of cinnamon, a widely-used food spice and flavoring material, and its metabolite sodium benzoate (NaB), a widely-used food preservative and a FDA-approved drug against urea cycle disorders in humans, in increasing the levels of neurotrophic factors [e.g., brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3)] in the CNS. NaB, but not sodium formate (NaFO), dose-dependently induced the expression of BDNF and NT-3 in primary human neurons and astrocytes. Interestingly, oral administration of ground cinnamon increased the level of NaB in serum and brain and upregulated the levels of these neurotrophic factors in vivo in mouse CNS. Accordingly, oral feeding of NaB, but not NaFO, also increased the level of these neurotrophic factors in vivo in the CNS of mice. NaB induced the activation of protein kinase A (PKA), but not protein kinase C (PKC), and H-89, an inhibitor of PKA, abrogated NaB-induced increase in neurotrophic factors. Furthermore, activation of cAMP response element binding (CREB) protein, but not NF-κB, by NaB, abrogation of NaB-induced expression of neurotrophic factors by siRNA knockdown of CREB and the recruitment of CREB and CREB-binding protein to the BDNF promoter by NaB suggest that NaB exerts its neurotrophic effect through the activation of CREB. Accordingly, cinnamon feeding also increased the activity of PKA and the level of phospho-CREB in vivo in the CNS. These results highlight a novel neutrophic property of cinnamon and its metabolite NaB via PKA -CREB pathway, which may be of benefit for various neurodegenerative disorders.
Introduction
Neurotrophic factors are a family of molecules that stimulate and control neurogenesis and support the survival of existing neurons. Consistently, in neurodegenerative disorders, which are hallmarked by the loss of neurons, neurotrophic factors have been suggested as rescuers of these vulnerable cells. Various neurotrophic molecules including brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) exhibit protective effects in cell culture as well as animal models of different neurodegenerative disorders (Phillips et al. 1991; Arenas and Persson 1994; Mamounas et al. 1995; Durany et al. 2000; Howells et al. 2000; Porritt et al. 2005) . However, clinical application of those molecules has been limited because of difficulties in delivery. These small proteins do not readily diffuse across the blood-brain barrier (BBB) or ventricular lining and have limited or unstable bioavailability (Rangasamy et al. 2010) . Gene delivery and/or protein delivery by stereotactic injection is definitely an option but it has several limitations (Huang and Mucke 2012) . It seems from the therapeutic angle, the best option is to stimulate/induce the production of neurotrophic factors within the CNS of patients with neurodegenerative and neuroinflammatory diseases. Therefore, finding out drugs or small molecules to upregulate neurotrophic factors within the CNS represents an important area of research.
Cinnamon, the brown bark of cinnamon tree, is a commonly used spice and flavoring material for deserts, candies, chocolate, etc. It has a long history as a medicine as well. Medieval physicians used cinnamon in medicines to treat a variety of disorders including arthritis, coughing, hoarseness, sore throats, etc. It was once so highly-prized that several wars were fought over it. In addition to containing manganese, dietary fiber, iron, and calcium, cinnamon contains a major compound, cinnamaldehyde, which is converted into cinnamic acid by oxidation. In the liver, this cinnamic acid is β-oxidized to benzoate (Abd El-Mawla et al. 2001 ) that exists as sodium salt (NaB) or benzoyl-CoA. It has been reported that minor amount of NaB is also excreted in the urine of human (Bridges et al. 1970; Kubota and Ishizaki 1991) . NaB is of medical importance as it is a component of Ucephan, a FDA-approved drug used in the treatment for hepatic metabolic defects associated with hyperammonemia such as urea cycle disorder in children (Leonard and Morris 2002; Scaglia et al. 2004) . It is also widely used as a preservative in broad range of foods and cosmetic products (Nair 2001) . It is non-toxic and can be administered as a solution in drinking water. It has been reported that 2 % solution of NaB in drinking water is safe for lifelong treatment in mice without any noticeable side effects (Toth 1984) . Recently we have delineated that NaB is capable of modulating both innate and adaptive immune responses (Brahmachari and Pahan 2007; Brahmachari et al. 2009; Brahmachari and Pahan 2010) .
Here we provide the first evidence about the neurotrophic function of cinnamon metabolite NaB. Neurotrophic factors could be produced from both neurons and glial cells. While neurons produce more neurotrophins than glia under physiological conditions, glial cells produce more neurotrophins than neurons under pathophysiological conditions. We show that NaB increases the expression of neurotrophic factors (BDNF and NT-3) in brain cells and in vivo in the CNS of mice. Accordingly, oral administration of cinnamon increased the level of NaB in vivo in the CNS and upregulated CNS expression of neurotrophic factors. Furthermore, we demonstrate that NaB utilizes the PKA -CREB pathway for the upregulation of neurotrophic factors. Our findings raise a possibility that cinnamon and NaB may find further application in neurodegenerative disorders via increased production of neurotrophic factors.
Materials and methods
Reagents Sodium benzoate (NaB) and sodium formate (NaFO), were purchased from Sigma Aldrich (St. Louis, MO). Original Ceylon cinnamon (Cinnamonum verum) in ground form was obtained from Indus Organics (San Ramon, CA). Cinnamonum cassia (1,000 mg capsules) was purchased from a Chicago area Walgreen. Fetal bovine serum (FBS), Hank's balanced salt solution (HBSS), trypsin, and DMEM/F-12 were from Mediatech (Manassas, VA). Neurobasal media and B27 supplement were purchased from Invitrogen (Grand Island, NY).
Mass spectrometric analysis A JEOL GCMate II (JEOL USA, Peabody MA) gas chromatograph/mass spectrometer was used in these experiments. The gas chromatography column was a fused silica capillary column with a nonpolar 5 % phenyl 95 % dimethylpolysiloxane phase (Agilent HP-5 ms), 30 m long, 0.25 mm internal diameter, 0.25 μm film thickness. The carrier gas was Helium (99.9995 % Research Grade) run through a STG triple filter (Restek Corp.) at a constant flow rate of 1.1 ml/min. The injector was held at 275°C and was fitted with an Agilent 4 mm ID single taper split liner containing deactivated glass wool. The spectrometer was operated in full scan EI mode (+Ve) at 70 eV scanning from m/z 10 to m/z 850 using a linear magnet scan. The scan speed was 0.3 s per scan. The solvent delay was 4.0 min. Data analysis was performed using the TSSPro software (Shrader Analytical & Consulting Laboratoies, Inc., Detroit MI). Total ion current (TIC) chromatographic peaks were used for quantitation. Mass calibration was performed using perflourokerosene.
Isolation of primary human neurons Human primary neurons were prepared as described by us earlier (Jana et al. 2007; Jana and Pahan 2010) . All of the experimental protocols were reviewed and approved by the Institutional Review Board of the Rush University Medical Center. Briefly, 11-17-week-old fetal brains obtained from the Human Embryology Laboratory (University of Washington, Seattle, WA) were dissociated by trituration and trypsinization (0.25 % trypsin in PBS at 37°C for 15 min). The trypsin was inactivated with 10 % heat-inactivated fetal bovine serum (Mediatech). The dissociated cells were filtered through 380-and 140-μm meshes (Sigma Aldrich) and pelleted by centrifugation. The cell pellet was washed once with PBS and once with Neurobasal medium containing 2 % B27 and 1 % antibiotic-antimycotic mixture (Sigma). In the first step, neurons were enriched by allowing the cells (3×10 treatment, the cells were used for this study. More than 98 % of this preparation was positive for microtubule-associated protein-2 (MAP-2), a marker for neurons.
Preparation of primary human astrocytes Primary human astrocytes were prepared as described by us earlier (Jana et al. 2007; Jana and Pahan 2010) .
Semi-quantitative RT-PCR analysis To remove any contaminating genomic DNA, total RNA was digested with DNase. Semi-quantitative RT-PCR was carried out as described earlier (Saha et al. 2006; Ghosh and Pahan 2012; Khasnavis and Pahan 2012 ) using a RT-PCR kit from Clonetech (Mountain View, CA). Briefly, 1 μg of total RNA was reverse transcribed using oligo(dT) 12-18 as primer and MMLV reverse transcriptase (Clontech). The resulting cDNA was appropriately-diluted, and diluted cDNA was amplified. Amplified products were electrophoresed on a 1.8 % agarose gels and visualized by ethidium bromide staining.
BDNF
Sense: 5′-TGAGGACCAGAAAGTTCGGC-3′ Antisense: 5′ -CAGTCTTTTTGTCTG CCGCC-3′ NT-3
Sense: 5′-TTTCTCGCTTATCTCCGTGGCATCC-3′ Antisense: 5′-GGCAGGGTGCTCTGGTAAT TTTCC T-3′ CREB Sense: 5′-ACCAGGAGTGCCAAG GAT TGAAGA-3′ Antisense: 5′-TTTGTACGTCTCCAGAG GCAGCTT-3′ GAPDH Sense: 5′-GGTGAAGGTCGGTGTGAACG3′ Antisense: 5′-TTGGCTCCACCCTTC AAGTG-3′
Real-time PCR analysis It was performed using the ABIPrism7700 sequence detection system (Applied Biosystems, Foster City, CA) as described earlier (Roy et al. 2007; Ghosh and Pahan 2012; Khasnavis and Pahan 2012) . The mRNA expressions of respective genes were normalized to the level of GAPDH mRNA. Data were processed by the ABI Sequence Detection System 1.6 software and analyzed by ANOVA.
Preparation of nuclear extracts and electrophoretic mobility shift assay DNA-binding activities of CREB and NF-κB were analyzed by non-radioactive electrophoretic mobility shift assay (EMSA) as described (Corbett et al. 2012; Mondal et al. 2012) . After treatment, cells were washed with HBSS, scraped into 1.5 mL tubes and centrifuged in 4°C for 5 min at 500 rpm. The supernatant was aspirated and the pellet was resuspended in a membrane lysis buffer comprised of (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (HEPES, pH8.0), MgCl 2 , KCl, dithiothreitol (DTT) and protease/phosphatase inhibitors (Sigma Aldrich), vortexed and centrifuged in 4°C at 720×g for 5 min. Again, the supernatant was aspirated and the pellet was resuspended in a high salt, nuclear envelope lysis buffer comprised of HEPES (pH8.0), MgCl 2 , glycerol, NaCl, ethylenediaminetetraacetic acid (EDTA), DTT and protease/phosphatase inhibitors, rotated vigorously in 4°C for 15 min and centrifuged in 4°C at 13,000 rpm for 15 min. The resultant supernatant was complexed with a cocktail of binding buffer (Tris-HCl, KCl, EDTA, DTT, 10x TGE, glycerol and Triton-X 100), custom designed fluorescent CREB-specific or NF-κB-specific probes (Li-Cor Biosciences, Lincoln, NE), and salmon sperm DNA (Invitrogen) for 15 min at room temperature and electrophoresed on custom-cast 6 % polyacrylamide-TGE gels in 1X TGE for 2 h. Supershift was performed by incubating nuclear extracts with 2 μg ChIP-grade CREB antibody or IgG (EMD Millipore, Billerica, MA) for 30 min prior to addition of the probe. The shift was visualized under the Odyssey® Infrared Imaging System (Li-Cor).
Chromatin immunoprecipitation Recruitment of CREB to the BDNF promoter was determined using the EZ ChIP kit from EMD Millipore as described by us (Corbett et al. 2012; Ghosh and Pahan 2012) . Briefly, 1×10 6 astrocytes were treated with NaB and after 2 h of treatment, cells were fixed by adding formaldehyde (1 % final concentration), and cross-linked adducts were resuspended and sonicated. ChIP was performed on the cell lysate by overnight incubation at 4°C with 2 μg of Abs against CREB and CBP followed by overnight incubation with protein G-agarose (Santa Cruz Biotechnology, Dallas, TX). The beads were washed and incubated with elution buffer. To reverse the cross-linking and purify the DNA, precipitates were incubated in a 65°C incubator overnight and digested with proteinase K. DNA samples were then purified, precipitated, and precipitates were washed with 75 % ethanol, air-dried, and resuspended in Tris-EDTA buffer. The following primers were used to amplify fragments flanking the CRE in the mouse exon IV-BDNF promoter: sense: 5′-TCATCACTCACGACCACGTC-3′, antisense: 5′-CCAGCCGGCTACTGCTTTA-3′. PCR products were electrophoresed on 2 % agarose gels.
Assay of BDNF by ELISA Level of BDNF was monitored in supernatants and cell homogenates by high-sensitivity ELISA kit (Promega, Madison, WI) as described before (Saha et al. 2006; Roy et al. 2007 ).
Immunofluorescence analysis It was performed as described earlier (Corbett et al. 2012; Ghosh and Pahan 2012) . Briefly, cover slips containing 100-200 cells/mm 2 were fixed with Fig. 1 Induction of neurotrophic factors by NaB, but not sodium formate (NaFO), in primary human neurons. Primary neurons were treated with 250 μM NaB or NaFO for different time intervals followed by monitoring the mRNA expression of BDNF and NT-3 by semi-quantitative RT-PCR (a). Cells were treated with different concentrations of NaB and NaFO for Statistics Statistical comparisons were made using one-way analysis of variance followed by Student's t test.
Results
Sodium benzoate (NaB) upregulates BDNF and NT-3 in primary human neurons Although there is growing knowledge about the role of neurotrophins in the health and survival of neurons, stem cells as well as oligodendrocytes, little is known about the drugs and associated molecular mechanisms that upregulate neurotrophins. Under physiological conditions, neurons are major producers of neurotrophic factors (Park and Poo 2013) . We examined if NaB could stimulate the expression of neurotrophins in primary human neurons. We found that NaB indeed increased the mRNA expression of both BDNF and NT-3 in a time-dependent (Fig. 1a) and dose-dependent ( Fig. 1b-d) manner. This result was specific as sodium formate (NaFO) had no effect on the expression of neurotrophic factors in neurons ( Fig. 1a-d) . We further checked the protein level of BDNF in neurons. As evident from immunofluorescence in Fig. 1e and ELISA in Fig. 1f , NaB, but not NaFO, increased the protein level of BDNF in human neurons. This result was not due to any change in cell viability as MTT assays (Fig. 1g) showed that NaB remained unable to modulate the viability of neurons.
Astrocytes, the major cell type in the CNS, also produce neurotrophic factors (Saha et al. 2006; Park and Poo 2013) . Therefore, next we examined if NaB could stimulate the expression of neurotrophic factors in primary human astrocytes. Consistent to human neurons, NaB strongly increased the mRNA expression of BDNF and NT-3 in human astrocytes in a time-dependent (Fig. 2a-c) and dose-dependent (Fig. 2d) manner. Again, NaFO remained unable to induce the expression of BDNF and NT-3 in astrocytes, suggesting the specificity of this effect. Double-label immunofluorescence showed that NaB, but not NaFO, markedly stimulated the expression of BDNF in astrocytes (Fig. 2e) . ELISA results also showed that NaB at a dose of 250 or 500 μM increased the level of BDNF protein in human astrocytes by about four fold (Fig. 2f) .
Composition of different types of cinnamon Next, we concentrated on cinnamon itself if cinnamon could upregulate neurotrophic factors in the brain. However, cinnamon contains different types of compounds and there are different types of cinnamon as well. Chinese cinnamon (Cinnamonum cassia) and original Ceylon cinnamon (Cinnamonum verum or Cinnamonum zylencum) are two major types of cinnamon that are available in the US. Therefore, we analyzed the composition of these two types of cinnamon powder by mass spectrometry. Although cinnamaldehyde was present as the major peak in both Cinnamonum cassia (Fig. 3a) and Cinnamonum verum (Fig. 3b) , Cinnamonum cassia contained more styrene, benzene, 1,1′-(2-butene-1,4-diyl)bis-, benzene, 1,1′-(1,2-cyclobutanediyl)bis-, palmitic acid, stearic acid, 4-phenylbutyl chloride, and (2,3-diphenylcyclopropyl)methyl phenyl sulfoxide than Cinnamonum verum (Fig. 3a-b) . Furthermore, Cinnamonum cassia contained a peak at 9.18 min, which corresponded to 1-benzopyran-2-one (commonly known as coumarin) (Fig. 3a) . Interestingly, Cinnamonum verum did not contain any coumarin. Since it has been reported that at higher dose, coumarin could be toxic for the liver and kidney, we performed further studies with only Cinnamonum verum. Before using Cinnamonum verum in mouse, we also quantified the level of cinnamaldehyde in Fig. 3 Mass spectrometric analysis of cinnamon extract. One gm cinnamon powder (a, Cinnamonum cassia; b, Cinnamonum verum) was solubilized in 5 ml acetonitrile by vortexing for 5 min. After centrifugation, the extract was loaded onto a GC mass spectrometer (JEOL GCmate). Different peaks [I, styrene; II, benzaldehyde; III, cinnamaldehyde; IV, cinnamic acid; V, benzopyran-2-one or coumarin; VI, benzene, 1,1′-(2-butene-1,4-diyl)bis-; VII, benzene, 1,1′-(1,2-cyclobutanediyl)bis-, trans-; VIII, palmitic acid; IX, stearic acid; X, 4-phenylbutyl chloride; XI, (2,3-diphenylcyclopropyl)methyl phenyl sulfoxide] were identified in the University of Illinois at Chicago Research Resources Center (UIC RRC) using the NIST Mass Spectral Database Library. c) Since cinnamaldehyde was found to be the major peak, a standard curve for cinnamaldehyde was made to quantify the level of cinnamaldehyde in cinnamon extracts. Results represent three independent experiments this type of cinnamon using the standard curve (Fig. 3c) . We found that the concentration of cinnamaldehyde in acetonitrile extract of Cinnamonum verum was 2.15 mM. Upon calculation, it has been seen that Cinnamonum verum contains 2.84 mg cinnamaldehyde per gm of cinnamon powder. However, it is possible that all cinnamaldehyde of cinnamon powder was not extracted in acetonitrile because only 20% of total mass of cinnamon was solubilized in acetonitrile.
Oral administration of Cinnamonum verum powder produced NaB in vivo in serum and brain of mice Theoretically cinnamon should be metabolized into NaB. However, there is no quantitative data available on the level of NaB in cinnamonfed animals. We examined if oral administration of Cinnamonum verum powder to mice increased the level of NaB in serum and brain of C57/BL6 mice. Ibuprofen was used as an internal standard. By HPLC, we could not detect any NaB in serum (Fig. 4a) and midbrain ( Fig. 4d ) of vehicle-fed mice. The sharp peak in Fig. 4c represents pure NaB. Oral treatment of mice with ground cinnamon (200 mg/kg body wt/d) via gavage markedly increased the level of NaB in serum (Fig. 4b) and midbrain (Fig. 4e ). These results demonstrate that cinnamon is metabolized into NaB and that cinnamon-derived NaB is capable of entering into the CNS.
In order to understand the pharmacokinetics of cinnamon, mice were gavaged cinnamon powder, which was mixed in 0.5% methylcellulose, at a dose of 100 mg/kg body wt/d, and at different time points, the concentrations of NaB in serum was monitored by HPLC. These data were analyzed using the Phoenix WinNonlin pharmacokinetics modeling software (Pharsight, Mountain View, CA) to calculate half-life (9.7 h), Tmax (18 h), Cmax (9.5 μg/ml), and clearance (CL_F) (522.6 ml/h/kg) (Fig. 4f) .
Oral administration of Cinnamonum verum powder and NaB increases the expression of neurotrophic factors in the brain of mice Because NaB increased the expression of neurotrophins in cultured astrocytes and neurons, we examined if NaB was capable of doing so in vivo in the brain. After 10 days of oral administration, NaB markedly increased the mRNA expression of BDNF and NT-3 (Fig. 5a for RT-PCR; Fig. 5b for real-time) in the cortex of male C57/BL6 mice. This result was specific as NaFO feeding did not increase the mRNA expression of these neurotrophic factors (Fig. 5a-b) . As evident from ELISA, NaB, but not NaFO, also increased the level of BDNF protein in the cortex (Fig. 5c) . Next, we examined if cinnamon itself could also increase these invaluable molecules in vivo in the brain. Interestingly, after 10 days of feeding, Cinnamonum verum powder markedly increased the mRNA expression of BDNF and NT-3 in the cortex (Fig. 5d ). Western blot (Fig. 5e) and ELISA ( Fig. 5f ) results showed that cinnamon feeding markedly increased the level of BDNF protein in vivo in the cortex. These results were also supported by immunofluorescence analysis of cortical sections, which showed that cinnamon treatment increased the level of BDNF in both NeuN-positive neurons (Fig. 5g) and GFAP-positive astrocytes (Fig. 5h) .
NaB requires CREB for the upregulation of neurotrophic factors Next, we investigated mechanisms by which NaB upregulated neurotrophic factors in brain cells. Because neurotrophins have long been thought to be under the transcriptional control of CREB (West et al. 2001; Tardito et al. 2006) , we analyzed the effect of NaB on the activation of CREB. As analyzed by EMSA, NaB, but not NaFO, induced the DNA-binding activity of CREB in primary human astrocytes in a time-dependent manner with maximum activation visible at 60 min of stimulation (Fig. 6a) . Super-shift assay confirmed the presence of CREB in NaB-induced DNA:protein complex (Fig. 6c) . Activation of CREB by NaB was specific as neither NaB nor NaFO had any effect on the activation of NF-κB (Fig. 6b) . Next, we examined the effect of cinnamon on the activation of CREB in vivo in the brain. In this case, we examined the activation of CREB by monitoring levels of phosphorylated CREB (p-CREB). Similar to the effect of NaB in cultured astrocytes, oral administration of cinnamon markedly increased the phosphorylation of CREB in vivo in the cortex of mice as depicted by Western blot (Fig. 6d-e) . This finding was also confirmed by double-label immunofluorescence that shows increase in phosphor-CREB in NeuN-positive neurons in the cortex of cinnamon-, but not vehicle-, fed mice (Fig. 6f) . Fig. 4 Oral administration of cinnamon powder (Cinnamonum verum) markedly increases the level of NaB in serum and brain of C57/BL6 mice. After 10 days of either vehicle (a) or cinnamon (200 mg/kg body wt/d) (b) feeding via gavage, mice were sacrificed followed by isolation of blood serum. Ibuprofen was added to serum as an internal standard. Serum was analyzed for the detection of NaB in Waters 2695 separation module HPLC system with the help of "Em-power pro" software and Phenomenex Luna 5 μ C18 100A column (250× 4.6 mm; 280-nm UV wavelength) using mobile phase A (acetonitrile with 0.01M H 3 PO 4 ) and mobile phase B (H 2 O with 0.01M H 3 PO 4 ) (1:4) at the flow rate of 0.5 ml/min. c) Chromatogram for 2.78 ng pure NaB. Similarly, after cinnamon feeding, midbrain tissue (d, vehiclefed; e, cinnamon-fed) was collected in chloroform: methanol (2:1) extraction solvent containing 0.05M perchloric acid. Ibuprofen was added as an internal standard. Tissues were homogenized and centrifuged at 20,000 g for 10 min. Organic and aqueous phases were separated carefully and 10 μl aqueous phase was analyzed for the detection of NaB by HPLC. f) For pharmacokinetic analysis in serum, mice were treated with one dose of cinnamon powder (100 mg/kg body wt) via gavage. At different time points, mice (n=3) were sacrificed and the concentration of NaB in serum was monitored by HPLC. These data were analyzed using the Phoenix WinNonlin pharmacokinetics modeling software (Pharsight, Mountain View, CA) to calculate halflife, Tmax, Cmax, and clearance (CL_F) Next, we investigated if NaB required CREB for the upregulation of neurotrophic factors in brain cells. At first, we examined if siRNA knockdown of CREB was capable of suppressing the expression of CREB protein in astrocytes. As evident from Fig. 7a-b , CREB siRNA, but not control siRNA, decreased the expression of CREB protein in control astrocytes. Accordingly, CREB siRNA, but not control siRNA, abrogated NaB-mediated upregulation of BDNF mRNA in astrocytes (Fig. 7c-d) . Similarly, CREB siRNA, but not control siRNA, also decreased NaB-induced upregulation of BDNF and NT-3 mRNAs in neurons (Fig. 7e-f) . These results suggest that NaB induces the activation of CREB, but not NF-κB, and that CREB is required for increased expression of neurotrophic factors in brain cells.
NaB induced the activation of CREB and the upregulation of BDNF via protein kinase A (PKA) CREB activity can be regulated by a number of signaling pathways. For example, stimuli that activate PKA and PKC result in CREB phosphorylation (Kandel 2012) . This prompted us to determine the upstream regulator of the NaB-mediated CREB activation. At first, we monitored if NaB alone was capable of activating PKA in human astrocytes. As evident from Fig. 8a , NaB alone induced the activation of PKA in astrocytes in a time-dependent manner and this activation was evident from as early as 15 min of stimulation. However, NaFO remained unable to activate PKA. Furthermore, NaB had no effect on the activation protein kinase C (PKC) (Fig. 8b) , indicating the specificity of its effect. Similarly, oral administration of cinnamon also caused the activation of PKA (Fig. 8c ), but not PKC (Fig. 8d) , in vivo in the cortex of mice. Next, we examined if NaB required PKA for the activation of CREB in astrocytes. Suppression of NaB-mediated activation of CREB by H-89 (Fig. 9a) suggests that NaB induces the activation of CREB via PKA. Accordingly, suppression of NaB-induced expression of BDNF mRNA (Fig. 9b-c) in astrocytes by H-89, a specific inhibitor of PKA, suggests that NaB upregulates BDNF in astrocytes via PKA.
NaB induces the recruitment of CREB to the BDNF promoter in astrocytes To further confirm the role of CREB in NaB-induced transcription of BDNF, we monitored the recruitment of CREB to the exon IV-BDNF promoter. Mouse exon IV-BDNF promoter harbors one CRE between 1,257 and 1,278 base pairs upstream of the transcriptional start site (Fig. 9d) . At first, we used ChIP analysis to study if NaB induced the recruitment of CREB to this CRE. After immunoprecipitation of NaB-treated astroglial chromatin fragments by Abs against CREB, we were able to amplify 165 bp fragment flanking the CRE and this amplification was missing in control astrocytes (Fig. 9e) , suggesting that NaB induces the recruitment of CREB to the BDNF promoter. Because CREB-binding protein (CBP), a histone acetyl transferase, plays an important role in CREBmediated many transcriptional activities, we investigated if CBP was also involved in NaB-induced transcription of BDNF. As evident from Fig. 9e , NaB treatment also induced the recruitment of CBP to the BDNF promoter. In contrast, no amplification product was observed in any of the immunoprecipitates obtained with control IgG (last lanes of Fig. 9e ), suggesting the specificity of these interactions. These results suggest that NaB alone is capable of increasing the recruitment of both CREB and CBP to the mouse exon IV-BDNF promoter. Therefore, next we examined if NaB stimulated this recruitment via PKA. Consistent to the inhibition of BDNF mRNA expression (Fig. 9b-c) , H-89 inhibited the recruitment of both CREB and CBP to the BDNF promoter in NaB-treated astrocytes (Fig. 9e ). These results demonstrate that NaB increases the recruitment of CREB and CBP to the BDNF promoter in astrocytes via PKA.
Discussion
Neurotrophic factors are secreted small proteins that are capable of signaling neurons to survive, differentiate, or grow. Furthermore, neurotrophic factors have also been suggested as rescuers of vulnerable neurons in many neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, HIV-associated dementia, in which the levels of some neurotrophic factors are significantly reduced in the brain. For example, it has been shown that the levels of BDNF and NT-3 are significantly downregulated in patients with Alzheimer's disease (AD) (Phillips et al. 1991; Durany et al. 2000) . Accordingly, these neurotrophic factors exhibit protective effects in cell culture as well as animal models of different neurodegenerative disorders (Arenas and Persson 1994; Howells et al. 2000 ; Fig. 5 Oral administration of NaB and cinnamon increases the level of neurotrophic factors in vivo in the CNS of mice. Six to eight week old male C57/BL6 mice (n=5 in each group) received different amounts of NaB via gavage and after 10 days of feeding, the mRNA expression of BDNF and NT-3 was monitored in the cortex by semi-quantitative RT-PCR (a) and real-time PCR (b). The protein level of BDNF in the cortex was quantified by ELISA (c). Similarly, mice (n=5 in each group) received different amounts of cinnamon powder (Cinnamonum verum) via gavage and after 10 days of feeding, the mRNA expression of BDNF and NT-3 was monitored in the cortex by semi-quantitative RT-PCR (d). Control mice received only vehicle (0.5% methylcellulose). The protein level of BDNF in the cortex was monitored by Western blot (e) and ELISA (f). Data are means ± SEM of five mice per group. Porritt et al. 2005) . Therefore, increasing the levels of these neurotrophic factors and/or maintaining their physiological levels in the CNS of patients with neurodegenerative disorders is/are an important area of research. However, such mechanisms are poorly understood.
Cinnamon is a commonly used flavoring material and its metabolite sodium benzoate (NaB) is a widely used food preservative and a FDA-approved drug for the treatment of urea cycle disorders in children. Earlier we have demonstrated that NaB modifies T cells at multiple steps and protects experimental allergic encephalomyelitis, an animal model of MS (Brahmachari and Pahan 2007) . Recently, it has been shown that orally administered cinnamon extract protects memory in a mouse model of AD (Frydman-Marom et al. 2011) . Several lines of evidence presented in this study clearly support the conclusion that cinnamon and its metabolite NaB are capable of upregulating neurotrophic factors. Our conclusion is based on the following observations. First, NaB dose-dependently induced the expression of BDNF and NT-3 in primary human astrocytes and neurons. This upregulation was specific as sodium formate (NaFO), a compound structurally similar to NaB but without having the benzene moiety, had no effect. Second, after oral feeding, NaB entered into the brain and upregulated BDNF and NT-3 in vivo in the brain. Third, oral administration of ground cinnamon increased the level of NaB in blood and brain of mice and upregulated BDNF and NT-3 in vivo in the brain. Because the loss of these neurotrophic factors has been implicated in the pathogenesis of various neurodegenerative diseases, our results provide a potentially important mechanism whereby cinnamon and its metabolite NaB may ameliorate or delay neurodegeneration.
The signaling events required for the transcription of neurotrophic factors are becoming clear. Upon analysis of the exon IV-BDNF promoter using the Genomatix Software Suite, we have found consensus binding sites for CREB, and NF-κB, C/EBPβ, and AP-1 in BDNF promoter. Although these transcription factors (CREB, NF-κB, C/EBPβ, and AP-1) may play a role in the expression of various neurotrophic factors, activation of CREB seems essential for the transcription of most of .001 vs NaB Fig. 6 Activation of CREB by NaB in primary human astrocytes and by cinnamon in vivo in the cortex of mice. Cells were incubated with 250 μM NaB or NaFO for different time periods followed by monitoring the activation of CREB (a) and NF-κB (b) by EMSA. c) Supershift assay was performed using antibodies against CREB. IgG was used as control. Mice (n=5 in each group) received different amounts of cinnamon powder (Cinnamonum verum) via gavage and after 10 days of feeding, levels of phospho-CREB and total CREB were monitored in the cortex by Western blot (d). Bands were scanned and presented as relative to control (e). Data are means ± SEM of five mice per group. s p<0.001 vs control. Control mice received only vehicle (0.5% methylcellulose). Cortical sections were also doublelabeled for NeuN & phospho-CREB (f) . Results represent analysis of two sections of each of five mice per group the neurotrophic factors (Saha et al. 2006; Roy et al. 2007; Kandel 2012) . Therefore, for a drug to exhibit neurotrophic effect, it is almost mandatory to stimulate the activation of CREB. Activation of CREB in cultured glial cells by NaB and in vivo in the CNS by cinnamon feeding and abrogation of the ability of NaB to induce neurotrophic factors by siRNA knockdown of CREB suggest that NaB increases the levels of neurotrophic factors via CREB. Although the activation of NF-κB has also been shown to be involved in the expression of neurotrophic factors, NaB alone does not induce the activation of NF-κB. Furthermore, earlier we have found that in activated glial cells, NaB inhibits the activation of NF-κB (Brahmachari et al. 2009 ). Therefore, NaB does not upregulate the expression of trophic factors via NF-κB.
However, it was unknown by which mechanisms NaB induced the activation of CREB in brain cells. The cAMPprotein kinase A (PKA) pathway, one of the most common and versatile signal pathways in eukaryotic cells, is involved in the regulation of multiple cellular functions including cell growth, differentiation, survival, and synaptic plasticity (Taylor et al. 2008; Kandel 2012) . PKA is a holoenzyme composed of two distinct subunits: regulatory (R) and catalytic (C). These regulatory and catalytic subunits form a tetrameric holoenzyme (R 2 C 2 ) (Taylor et al. 1995 (Taylor et al. , 2008 . In the absence of cAMP, PKA exists as a stable inactive tetramer (Taylor et al. 1995 (Taylor et al. , 2008 . After an increase in intracellular cAMP, the regulatory PKA subunits bind to cAMP in a cooperative manner, resulting in the conformational change in the regulatory subunits and disassociation of the holoenzyme into an R 2 (cAMP) 4 dimer and two monomers of catalytically active kinase (Taylor et al. 1995 (Taylor et al. , 2008 . Here we present evidence that NaB induced the activation of CREB via PKA. While both protein kinase C (PKC) and protein kinase A (PKA) are known to phosphorylate and activate CREB, NaB specifically induced the activation of PKA. Suppression of PKA by H-89 inhibited NaB-induced activation of CREB and expression of neurotrophic factors. However, at present, we do not know mechanisms by which NaB induces PKA. In general, PKA signaling pathway is transduced from G proteins (Taylor et al. 1995 (Taylor et al. , 2008 . Of the various Gα isoforms, G s α stimulates adenylyl cyclase, whereas G i α mediates the inhibition of adenylyl cyclase. The activation of adenylyl cyclase catalyzes the conversion of adenosine triphosphate to cAMP, which then serves as a second messenger and activates PKA. Because NaB induces the activation of PKA within minutes, it may not be surprising if NaB uses any of the G proteins to activate PKA.
PKA has several key functions in the cell, including of glycogen, sugar and lipid metabolism. Therefore, our results suggest that cinnamon and NaB may also participate in glucose and lipid metabolism. In fact, in a 2003 clinical (Khan et al. 2003) . The same study has also reported a decrease of cholesterol by 12 to 26 % by oral administration of cinnamon in same patients. In a recent study, we have also demonstrated that NaB antagonizes the mevalonate pathway and reduces blood cholesterol at a level that is comparable to cholesterollowering drug pravastatin (Brahmachari et al. 2009 ).
There are several advantages of NaB and cinnamon over other proposed anti-neurodegenerative therapies. First, both NaB and cinnamon are fairly nontoxic. Cinnamon has been widely used as flavoring material and spice throughout the world for centuries. Cinnamon is metabolized to NaB. NaB is excreted through the urine, if in excess. NaB is an FDAapproved drug against Urea cycle disorders in children. Second, cinnamon and NaB can be taken orally, the least painful route. Recently, we have demonstrated that NaB treatment of mice with relapsing-remitting EAE, an animal model of MS, via drinking water suppressed the disease process of EAE (Brahmachari and Pahan 2007) . Oral administration of cinnamon extract exhibits neuroprotective effect in a mouse model of AD. (Frydman-Marom et al. 2011 ) Third, cinnamon and NaB are very economical compared to other existing anti-neurodegenerative therapies. Fourth, after oral administration, NaB rapidly diffuses through the BBB. Similarly, after oral administration of cinnamon, we also detected NaB in the brain. Fifth, glycine toxicity is a problem in different neurological diseases because for movement disorders, glycine is one of the factors for inhibiting motor neurons (Iwasaki et al. 1992) . When impaired, glycinergic inhibition leads to spastic and hypertonic disorders such as featured in PD, multiple sclerosis (MS) and spinal cord trauma. NaB is known to combine with glycine to produce hippurate, a compound that is readily excreted in the urine (Mitch and Brusilow 1982) . Because PD and MS patients exhibit significant elevation in plasma level of glycine (Iwasaki et al. 1992; Barkhatova et al. 1998 ), NaB and cinnamon may have added benefits for MS and PD.
In summary, we have demonstrated that cinnamon (an easily-available and widely-used natural compound) and NaB (a metabolite of cinnamon, commonly-used food additive and a FDA-approved drug for urea cycle disorders) upregulate neurotrophic factors via PKA-mediated activation of CREB. These results highlight undiscovered properties of cinnamon and NaB and indicate that these compounds may be used for therapeutic intervention in neurodegenerative disorders as primary or adjunct therapy.
